Boston Scientific Corp., founded in 1979 and headquartered in Marlborough, Massachusetts, is a leading global medical device manufacturer focused on innovation that transforms lives through less-invasive therapies. The company specializes in products addressing a wide range of medical conditions including cardiovascular, digestive, and urological diseases, offering advanced solutions that enhance patient outcomes and healthcare efficiency.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| BSX 0.63% 2027-12-01 EURBoston Scientific Corp. | United States | 2027-12-01 | 0.625 | 2.69 |
| BSX 1.90% 2025-06-01 USDBoston Scientific Corp. | United States | 2025-06-01 | 1.900 | 15.27 |
| BSX 2.65% 2030-06-01 USDBoston Scientific Corp. | United States | 2030-06-01 | 2.650 | 4.14 |
| BSX 3.75% 2026-03-01 USDBoston Scientific Corp. | United States | 2026-03-01 | 3.750 | 4.50 |
| BSX 4.00% 2028-03-01 USDBoston Scientific Corp. | United States | 2028-03-01 | 4.000 | 3.85 |
| BSX 4.00% 2029-03-01 USDBoston Scientific Corp. | United States | 2029-03-01 | 4.000 | 4.05 |
| BSX 4.55% 2039-03-01 USDBoston Scientific Corp. | United States | 2039-03-01 | 4.550 | 4.94 |
| BSX 4.70% 2049-03-01 USDBoston Scientific Corp. | United States | 2049-03-01 | 4.700 | 5.30 |
| BSX 6.75% 2035-11-15 USDBoston Scientific Corp. | United States | 2035-11-15 | 6.750 | 4.91 |
| BSX 7.38% 2040-01-15 USDBoston Scientific Corp. | United States | 2040-01-15 | 7.375 | 5.21 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Boston Scientific has a robust history of bond issuances, with its inaugural bond offerings dating back to the early 1990s. Notably, in 2021, the company issued $1 billion in senior notes to fund its acquisition of the electrophysiology technology firm, providing a yield of 3.0%—competitive within the medical device sector. Their bonds typically include call options allowing for early redemption, reflecting flexible financial management strategies. As of late 2023, Boston Scientific’s bond yields remain steady amid industry fluctuations, contributing to investor interest in their securities.